A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19
Kim Ys, Seng‐Ho Jeon, Jung-Hee Kim, Jung-Hee Kim, Jong Hoon Koh, Seung Won, Ji Won Kim, Ji Won Kim, Yeonjae Kim, Choon Kwan Kim, Yun Chul Shin, Beodeul Kang, Seung‐Ji Kang, Chul Hee Park, Bo‐Young Lee, Ji Yeon Lee, Chung Hoon Lee, Jae‐Phil Choi, Jin Yong Kim, Jin Yong Kim, Shi Nae Yu, Kyong Ran Peck, Sung‐Han Kim, Jung Yeon Heo, Hyun Ah Kim, Hyunjin Park, Jong-Won Choi, Jumi Han, JooHyun Kim, JooHyun Kim, Hyoung jun Kim, Se Hee Han, Aeri Yoon, MiHee Park, SuJung Park, Yukyung Kim, Minji Jung, Myoung‐don Oh
Abstract
= 0.21). Adverse events were similar in the two groups. Camostat mesylate was safe in the treatment of COVID-19. Although this study did not show clinical benefit in patients with mild to moderate COVID-19, further clinical studies for high-risk patients are needed. (This trial was registered with ClinicalTrials.gov under registration no. NCT04521296).